Results 41 to 50 of about 24,867 (223)
British Journal of Clinical Pharmacology, EarlyView.Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner +5 more
wiley +1 more source
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Īlām, 2021 Introduction: Human error plays a significant role in the occurrence of industrial accidents. Displacement and unloading operations are operations in which the occurrence of human error may lead to plenty of human and financial losses.
Reza Jafari Nodoushan +3 more
doaj
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Data Classification Methodology: The Way Forward to Data-Enabled Healthcare in Egypt [PDF]
Global Journal on Quality and Safety in HealthcareA robust data management system is crucial for healthcare entities to get value from the exponential volume of generated and stored data. Given the impact of data on the decision-making process at the individual, organizational, and institutional levels,
Gihan Hamdy Elsisi, Yousra Hamed
doaj +1 more source
„HTA und Impact“ – Erfahrungen der Deutschen Agentur für HTA
, 2011 [for full text, please go to the a.m. URL]
openaire +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
International Journal of Technology Assessment in Health Care, 2012 This issue of the International Journal of Technology Assessment in Health Care (IJTAHC) brings to the readers a lively discussion on the possibility of benchmarking health technology assessment (HTA) organizations. Michael Drummond and colleagues present a paper discussing “the conceptual and methodological challenges associated with benchmarking” (1).
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source
Organizational structure and funding of health technology assessment agencies around the world
Фармакоэкономика, 2019 Aim: analyze the structure and funding of health technology assessment (HTA) agencies abroad.Materials and methods. Here, we review the organizational structure and funding of HTA agencies in Europe (Austria, Belgium, Germany, Ireland, the Netherlands ...
G. R. Khachatryan +3 more
doaj +1 more source